In an attempt to induce temperature-sensitive (is) conditional lethal mutants of rabies virus, stocks of a plaque-purified substrain of strain CVS fixed rabies virus were subjected to mutagenesis by HNO2, 5-fluorouracil, or 5-azacytidine. It was necessary to prepare virus stocks from clones of mutagenized virus selected at random and to test subsequently each stock for possible ts characteristics by measuring its relative capacity for growth at permissive (33 C) and nonpermissive (40.5 C) temperatures. Five ts mutants were detected in tests of 161 clones of mutagenized virus. Each of the mutants exhibited a remarkably low incidence of reversion and little demonstrable "leakiness." One of the five ts mutants (ts2), which formed formed very small plaques, and another (tsl), which formed plaques of only slightly reduced size, were further characterized. Virus tsl was more thermostable at 40.5 C than the parental virus, but the ts2 mutant was unchanged in this respect. The tsl virus exhibited normal pathogenicity for mice, but ts2 virus caused a very irregular death pattern. Both deaths and survivors immune to rabies virus challenge were noted in all groups of mice inoculated with ts2 virus, regardless of the virus dose.
Although the viral etiology of rabies has been recognized for nearly a century (13) , application of modern virological techniques to the study of rabies virus has been possible only since its adaptation to growth in cell culture in 1958 by Kissling (6) . Rabies virus does not consistently produce a cytopathic effect or plaques in monolayer cell culture. The practical study of genetically homogeneous clones of rabies virus became possible only after the development of an agarosesuspended cell plaquing technique (15) . Unfortunately, this plaquing system tolerates only very narrow ranges of temperature and thus is not applicable to direct assay for temperature-sensitive (ts) conditional lethal mutants of rabies virus. Furthermore, plaque sizes vary for artifactual reasons in this system, so it has not been possible to select plaque-size variants from "wild" rabies populations.
TIhe CVS "fixed" strain of rabies virus replicates in BHK monolayer cell cultures at temperatures ranging from 25 C to over 40 C. Plaque assay is performed at 35 C. Maximum yield of released virus is obtained at 33 C, but a temperature of 35 C is used for clone outgrowth, as that is the lowest temperature supporting cell multiplication. In an attempt to isolate ts mutants of rabies virus, we have selected at random clones of virus populations treated with chemical mutagens and determined their relative capacity for growth at 33 C (permissive temperature) and 40.5 C (nonpermissive temperature). The isolation by these techniques of five ts mutants and the preliminary characterization of two mutants are described in this report. MATERLALS AND METHODS Cel cultures. BHK subclone 21 (BHK-21) cells were propagated in Eagle's basal medium with double concentrations of vitamins and amino acids (BME) with 0.225% HCO3-and 10% fetal calf serum (FCS) added (BME FCS 10). BHK subclone 13S (BHK-13S) cells were propagated in BHK growth medium (10) with 0.17% HCO3-and 10% FCS.
Virus. CVS strain virus that had been passed 112 times in primary hamster kidney cell culture (7) was kindly supplied to us by P. E. Halonen. The virus was passed twice in BHK-21 cells, clone-purified three times in BHK-13S cells, and passed two or three more times on BHK-21 cells prior to use. Virus stocks were routinely prepared in BHK-21 cell cultures infected at a cell multiplicity of 0.1 to 10.0 and incubated for 72 to 96 hr at 33 C in a medium consisting of BME plus 0.1% bovine serum albumin (BNME.1BA). Cell supernatant fluids clarified by centrifugation at 800 X g for 30 min at 4 C comprised the virus stock.
Virus cloning methods. All virus assays were performed by the agarose-suspended BHK-1 3S cell plaque technique (15 and suspended in 1.0 ml of BME.1BA. To prepare cloned virus stocks, 0.5 ml of plaque suspension was added to 1.5 X 106 BHK-21 cells suspended in 0.3 ml of growth medium. The mixture was incubated in 30-ml plastic tissue culture flasks (Falcon Plastics Co.) standing on end for 30 min at 33 C. After this adsorption period, 5.0 ml of growth medium was added to each flask, and the flasks were placed flat and incubated at 35 C for 4 to 6 days, after which the supernatant fluids were harvested. Cloned CVS virus stocks prepared in this manner contained 107-5 to 108.7 plaque-forming units (PFU)/ml.
Chemical mutagenesis: nitrous acid. The method of Granoff (4) 4.4 in which NaNO2 was replaced with NaCl, no reduction in virus titer was detected, thus establishing the specific role of the nitrous acid in the virus inactivation. The high degree of stability of rabies virus under acidic conditions of pH 54.5 has been previously reported by Turner and Kaplan (18) and by Kuwert and Liebenow (8) .
Effect of 5-FU and 5-AzaC on the replication of rabies virus. Incorporation of 5-FU in cell maintenance medium at a concentration of 2 mm led to a depression in rabies virus yield (after 48 hr incubation at 33 C) of from 65 to 85%. Under similar conditions, 5-AzaC at a concentration of 25 yg/ml led to a 97 to >99% reduction in rabies virus yield. Selection of rabies virus mutants. Initially, an attempt was made to select a heat-resistant CVS virus variant for production of a standard pool for chemical mutagenesis, to obviate the problem of the lability of rabies virus at high nonpermissive temperatures. Virus suspended in BME.1BA was heated at 60 C, and samples removed at various time intervals were titrated for residual infectivity. Several plaques were harvested from the titration of the last sample yielding surviving virus (5, 10, or 20 min) and used to prepare new virus stocks which were again heated at 60 C. After five such cycles of heating and regrowth of clones of surviving virus, no thermoresistant variants were obtained. The half-life at 60 C of the original CVS stock (suspended in BME.1BA) and of all the tested progeny clones (suspended in BME FCS 10) was approximately 36 sec. A clone designated CVS-HPP (CVS-heated and plaquepurified) was selected from the sixth heating experiment for use as a basic stock for mutagenesis because, although it was not demonstrably more heat-stable than the parental virus, it was assumed to be genetically homogeneous as a result of six consecutive clonings. Five ts mutant clones were detected in studies of 161 clones of mutagen-treated CVS-HPP virus. The incidence of mutant clones was 1 (tsl) of 44 treated with HNO2, 2 (ts2 and 3) of 91 grown in the presence of 5-AzaC, and 2 (ts4 and 5) of 26 grown in the presence of 5-FU.
The relative capacity of each mutant virus (in the 2nd or 3rd BHK-21 passage after clone selection) for growth at 40.5 and 33 C is shown in Table 1 . Although CVS stock virus gave yields at 40.5 C equal to 0.5 to 5.0% of those obtained at the permissive temperature, the mutant viruses, with a single exception, revealed no demonstrable replication at the nonpermissive temperature. The small amount of tsl progeny virus detected at 40.5 C was determined to be revertant non-ts virus. The results suggest that there is no measurable "leakiness" of these mutants at 40.5 C. An exact determination of reversion rates was not possible because of our technical inability to plaque rabies virus at the nonpermissive temperature. However, the total absence of detectable virus in 40.5-C cultures infected with four of the five mutants indicates that the incidence of revertants in those mutant stocks was less than one in 108 particles, the minimum amount of virus in the inocula tested.
Of the ts mutant clones, one, ts2, produced unusually small plaques, whereas the size of plaques produced by the other four was normal or near-normal (Fig. 1) The possibility that clones tsl and ts2 may represent thermolabile mutants was tested by thermoinactivation studies at 40.5 C (Fig. 2) . The results indicate that clone ts2 virus is inactivated at a rate very similar to that of the parental virus (half-life, ca. 4.1 hr). Clone tsl virus is actually more thermoresistant than the parental stock (half-life, 7.5 hr).
Pathogenicity for mice. The response of weanling mice to intracerebral inoculation with serial dilutions of parental type CVS and ts mutant viruses is depicted in Fig. 3 . Typical dose-response effects were observed with CVS, CVS-HPP, and mutant tsl viruses. The plaque-purified CVS virus appeared to be slightly less virulent for mice than the original CVS stock, causing greater than 50% mortality only at doses above 10 PFU, whereas the wild CVS stock was highly lethal even in doses of less than 1 PFU. Mutant tsl virus appeared slightly more pathogenic than the CVS-HPP stock from which it was derived, giving a dose-response curve similar to that of the CVS stock.
Mutant ts2 virus exhibited an extremely aberrant dose-response relationship. Both rabiesspecific deaths and survivors were observed in groups of mice receiving virus doses varying from ca. 1 (1) and influenza virus (9, 12) . Reduced pathogenicity in vivo has also been described in the case of small-plaque mutants of foot-and-mouth disease virus induced by hydroxylamine (11) As noted above, rabies virus is the second virus of the rhabdovirus group from which ts mutants have been described. ts Mutants of VSV have been obtained in large numbers from virus stocks subjected to chemical mutagenesis and an incidence of 0.9 to 5.0% ts mutants in wild VSV preparations has been estimated (3, 4, 14) . Complementation between appropriate ts mutants of VSV has been demonstrated to be unusually efficient, and recombination has been demonstrated. It has been possible to place the majority of VSV ts mutants within one of either four (14) or five (3) complementation groups. An adequate comparison of the genetic properties of rabies virus with those of VSV will require: (i) determination that the known rabies mutants represent single-point mutations, (ii) performance of tests for complementation and recombination, and (iii) the isolation of many more ts rabies mutants, an accomplishment which will undoubtedly require the development of new and more efficient means for screening rabies virus clones for the presence of the ts condition.
